Exendin-phe1 responses in human islets To gain insight into whether the beta cell effects of exendin-phe1 might translate to humans, we compared the responses of exendin-4 and exendin-phe1 in intact human islets
The most common adverse effects from the SURMOUNT trials include: Nausea: 24-33% of participants (dose-dependent) Diarrhea: 18-25% of participants Constipation: 13-17% of participants Vomiting: 8-12% of participants Decreased appetite: 10-15% of participants Most of these effects are mild to moderate and occur primarily during dose escalation periods
In addition to this, Tau acts via bridges between MTs and actin via its tubulin binding domains that facilitate formation of actin-tubulin cytoskeletal structures (Elie et al., 2015)
*Correspondence: Rui Cong [email protected] Zhao [email protected] This article was submitted to Neuromuscular Disorders and Peripheral Neuropathies, a section of the journal Frontiers in Neurology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The proportional hazards assumption was assessed using the generalized Schoenfeld method implemented within the TriNetX platform
Absolutely correct
